• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Curie-Cancer, Sanofi collaborate

Curie-Cancer, Sanofi collaborate

June 19, 2013
CenterWatch Staff

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Carnot Institute, have established a three-year research collaboration to identify new therapeutic targets for developing treatments for ovarian cancer.

The aim is to revisit the basic biology of cancer through a translational research approach. The Curie Institute has a collection of cryopreserved tumor samples characterized clinically, histologically and biologically. These can be analyzed to identify biological targets relevant to the effective treatment of cancer. Sanofi and Curie-Cancer expect to gain a better understanding of the molecular alterations that characterize many types of ovarian cancer, thereby enabling effective new drugs to be designed.

"We hope this long-term collaboration will ultimately open up perspectives for new therapeutic options for women with this disease," said Debasish Roychowdhury, senior vice president and head of Sanofi oncology.

Using technology platforms developed at the Curie Institute, this program will make it possible to sequence molecules expressed by the tumor genome, compare the sequences of those obtained with non-tumor tissues from the same patients and then clarify and validate the nature of the molecular alterations identified. Sanofi will guide an assessment of the tumor's ability to be inhibited or stimulated by drugs.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing